Companies: 10,795·Total market cap: $144.5T
Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc.

COCPNASDAQHealthcare● Active
$1.01
+$0.05(+4.74%)
Market Cap$10351957
P/E Ratio
52W High$2.67
52W Low$0.86

Cocrystal Pharma, Inc. (COCP) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

cocp · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Cocrystal Pharma, Inc. (COCP) measures how much investors pay for each dollar of the company's trailing earnings. COCP's current PE ratio of N/A is calculated by dividing its stock price of $1.01 by its TTM earnings per share of -$0.64.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2026 est. EPS $-0.69
Based on 2 analysts
EPS (TTM)
-$0.64
TTM · diluted EPS
PEG Ratio
-0.02
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cocrystal Pharma, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2007 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc.You
COCP
$10MN/A-$0.64
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
BOLT
$9MN/A-$17.85
BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc.
BRTX
$3MN/A-$1.58
Cingulate Inc.
Cingulate Inc.
CING
$25MN/A-$4.13
Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc.
DWTX
$3MN/A-$4.17
Evogene Ltd.
Evogene Ltd.
EVGN
$5MN/A-$1.08
Imunon, Inc.
Imunon, Inc.
IMNN
$5MN/A-$6.83

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 19 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-0.78
2024-12-31
FY2024
$-1.72
2023-12-31
FY2023
$-1.86
2022-12-31
FY2022
$-4.77
2021-12-31
FY2021
$-1.84
2020-12-31
FY2020
$-2.01
2019-12-31
FY2019
$-15.78
2018-12-31
FY2018
$-21.01
2017-12-31
FY2017
$-0.30
2016-12-31
FY2016
$-38.17

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Cocrystal Pharma, Inc. (COCP) measures how much investors pay for each dollar of the company's trailing earnings. COCP's current PE ratio of N/A is calculated by dividing its stock price of $1.01 by its TTM earnings per share of -$0.64.

PE Ratio = Stock Price ÷ EPS (TTM)
= $1.01 ÷ -$0.64 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

COCP pe ratio · 6 questions

COCP's current PE ratio is N/A as of 2026-06-08, based on a stock price of $1.01 and TTM EPS of -$0.64. Data sourced from Financial Modeling Prep via COCP's SEC 10-K and 10-Q filings.

COCP PE ratioWhat is COCP PE ratioCurrent PE ratio of COCPCOCP PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cocrystal Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08